BRPI0913436A2 - peptídeos de ep´topo de mybl2 e vacinas contendo oso mesmos - Google Patents

peptídeos de ep´topo de mybl2 e vacinas contendo oso mesmos

Info

Publication number
BRPI0913436A2
BRPI0913436A2 BRPI0913436A BRPI0913436A BRPI0913436A2 BR PI0913436 A2 BRPI0913436 A2 BR PI0913436A2 BR PI0913436 A BRPI0913436 A BR PI0913436A BR PI0913436 A BRPI0913436 A BR PI0913436A BR PI0913436 A2 BRPI0913436 A2 BR PI0913436A2
Authority
BR
Brazil
Prior art keywords
mybl2
same
epitope peptides
vaccines containing
vaccines
Prior art date
Application number
BRPI0913436A
Other languages
English (en)
Portuguese (pt)
Inventor
Ryuji Ohsawa
Takuya Tsunoda
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BRPI0913436A2 publication Critical patent/BRPI0913436A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0913436A 2008-06-10 2009-06-09 peptídeos de ep´topo de mybl2 e vacinas contendo oso mesmos BRPI0913436A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6029308P 2008-06-10 2008-06-10
PCT/JP2009/002587 WO2009150822A1 (en) 2008-06-10 2009-06-09 Mybl2 epitope peptides and vaccines containing the same

Publications (1)

Publication Number Publication Date
BRPI0913436A2 true BRPI0913436A2 (pt) 2015-12-01

Family

ID=41416535

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913436A BRPI0913436A2 (pt) 2008-06-10 2009-06-09 peptídeos de ep´topo de mybl2 e vacinas contendo oso mesmos

Country Status (13)

Country Link
US (1) US20110189213A1 (enExample)
EP (1) EP2297180A4 (enExample)
JP (1) JP2011522777A (enExample)
KR (1) KR20110016952A (enExample)
CN (1) CN102119170A (enExample)
AU (1) AU2009258775B2 (enExample)
BR (1) BRPI0913436A2 (enExample)
CA (1) CA2727482A1 (enExample)
IL (1) IL209870A0 (enExample)
MX (1) MX2010013688A (enExample)
RU (1) RU2496787C2 (enExample)
TW (1) TW201000119A (enExample)
WO (1) WO2009150822A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201200525A (en) * 2009-12-04 2012-01-01 Oncotherapy Science Inc MYBL2 peptides and vaccines containing the same
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
CN104017054B (zh) * 2014-06-25 2016-12-07 南安市威速电子科技有限公司 Per2蛋白激动剂多肽及其应用
CN104004062B (zh) * 2014-06-25 2016-03-16 刘元超 关于per2蛋白激动剂多肽及其应用
CN104045693B (zh) * 2014-06-25 2016-12-07 杨高林 一种关于per2蛋白激动剂多肽及其应用
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
WO2017203370A2 (en) * 2016-05-23 2017-11-30 The Council Of The Queensland Institute Of Medical Research Cmv epitopes
CN109963862B (zh) * 2016-09-07 2024-01-30 武汉华大吉诺因生物科技有限公司 多肽及其应用
CN109136376B (zh) * 2018-05-21 2021-09-21 中国医科大学附属第四医院 一种膀胱癌相关环状RNA的应用和siRNA及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0253486A (ja) * 1988-08-19 1990-02-22 Rikagaku Kenkyusho ヒトｍｙｂ関連遺伝子
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
AU2002349543A1 (en) * 2001-12-10 2003-06-23 Kyogo Itoh Tumor antigens
WO2004018667A1 (ja) * 2002-08-26 2004-03-04 Kirin Beer Kabushiki Kaisha ペプチド及びこれを含む医薬
CN101139392B (zh) * 2002-09-12 2012-12-26 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
CN1703522A (zh) * 2002-09-30 2005-11-30 肿瘤疗法科学股份有限公司 诊断睾丸精原细胞瘤的方法
US20050260639A1 (en) * 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
EP2947160B1 (en) * 2004-04-09 2017-07-12 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
JP4547197B2 (ja) * 2004-06-30 2010-09-22 公正 安元 癌特異的腫瘍抗原
JP2008511678A (ja) * 2004-09-02 2008-04-17 イェール ユニバーシティ マイクロｒｎａによるオンコジーンの調節
ES2319286T3 (es) * 2004-10-02 2009-05-06 Immatics Biotechnologies Gmbh Epitopos inmunogenos de linfocitos t colaboradores de antigenos de tumor humanos y utilizacion de dichos epitopos en metodos inmunoterapeuticos.
AU2005304878B2 (en) * 2004-11-05 2010-07-08 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
PL1836629T3 (pl) * 2004-11-05 2020-06-15 Genomic Health, Inc. Przewidywanie odpowiedzi na chemioterapię z zastosowaniem markerów ekspresji genu
CN101175862A (zh) * 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
CN101500597A (zh) * 2005-06-17 2009-08-05 伊姆克罗尼系统公司 治疗转移性骨癌的受体拮抗剂
WO2007013671A2 (en) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
EP2295571A1 (en) * 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
WO2007066423A1 (ja) * 2005-12-08 2007-06-14 Dainippon Sumitomo Pharma Co., Ltd. Ａｍａｃｒ由来の腫瘍抗原ペプチド
JP2009091249A (ja) * 2006-01-23 2009-04-30 Univ Kurume Ｃ型肝炎ウイルス２ａ由来ＨＬＡ−Ａ２拘束性抗原ペプチド
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer

Also Published As

Publication number Publication date
JP2011522777A (ja) 2011-08-04
US20110189213A1 (en) 2011-08-04
KR20110016952A (ko) 2011-02-18
TW201000119A (en) 2010-01-01
MX2010013688A (es) 2011-02-23
CN102119170A (zh) 2011-07-06
EP2297180A4 (en) 2011-11-09
CA2727482A1 (en) 2009-12-17
AU2009258775B2 (en) 2013-10-10
RU2496787C2 (ru) 2013-10-27
IL209870A0 (en) 2011-02-28
RU2010154101A (ru) 2012-07-20
AU2009258775A1 (en) 2009-12-17
EP2297180A1 (en) 2011-03-23
WO2009150822A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
IL211131A0 (en) Inhbb epitope and vaccines containing the same
BRPI0913436A2 (pt) peptídeos de ep´topo de mybl2 e vacinas contendo oso mesmos
GB2463586B (en) li-key/antigenic epitope hybrid peptide vaccines
IL209967A0 (en) Cdca1 epitope peptides and vaccines containing the same
IL220752A0 (en) Tem8 peptides and vaccines comprising the same
IL219048A (en) Peptide compounds derived from urcl10
IL209869A0 (en) Iqgap3 epitope peptides and vaccines containing the same
AU2009266430A8 (en) Anti- P2X7 peptides and epitopes
BRPI0917391A2 (pt) peptídeo de epítodo de hig2 e urlc10 e vacinas contendo o mesmo
IL210861A0 (en) Melk epitope peptides and vaccines containing the same
ZA201103667B (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
EP2076544A4 (en) ANTI-OBESITY IMMONOGENIC HYBRID POLYPEPTIDES AND ANTI-OBESITY VACCINE COMPOSITION COMPRISING THE SAME
IL213318A0 (en) C1orf59 peptides and vaccines including the same
IL214453A0 (en) Vangli peptides and vaccines including the same
IL219927A0 (en) Mybl2 peptides and vaccines containing the same
IL215268A0 (en) C6orf167 peptides and vaccines containing the same
ZA201104890B (en) Wdrpuh epitope peptides and vaccines containing the same
GB0716494D0 (en) HIV-2 antigenic peptides
HK1154875A (en) Mybl2 epitope peptides and vaccines containing the same
HK1155755A (en) Iqgap3 epitope peptides and vaccines containing the same
HK1157815A (en) Inhbb epitope peptides and vaccines containing the same
HK1138879A (en) Tem8 peptides and vaccines comprising the same
HK1172353A (en) Mybl2 peptides and vaccines containing the same
HK1159182A (en) C1orf59 peptides and vaccines including the same
TH0901004695A (th) Rab6kifl/kif20a อิพิโทป เปปไทด์ และ วัคซีนที่ ประกอบด้วยสิ่งเดียวกันนั้น

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.